Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA photodynamic therapy for non-melanoma skin cancer and precursor lesions in Chinese patients
ChiCTR1800019213Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 5-aminolevulinic acid in actinic keratosis (AK), basal cell carcinoma (BCC), Bowen disease (BD) and 1 more, sponsored by Peking University First Hospital. Primary endpoint: Complete response rate. Started Dec 2018; status: recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)basal cell carcinoma (BCC)Bowen disease (BD)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on ChiCTR1800019213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019213.